{"title":"中青年接种BNT162b2 mRNA后体重与抗sars - cov -2抗体水平呈负相关","authors":"Su Youn Nam, Seong Woo Jeon, Deuk Kju Jung, Sung-Jae Heo","doi":"10.3947/ic.2022.0089","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study aimed to determine factors affecting serum levels of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies 2 months after coronavirus disease 2019 (COVID-19) vaccination in young and middle aged healthy adults.</p><p><strong>Materials and methods: </strong>Healthcare workers who have no history of SARS-CoV-2 infection, were enrolled at 2 months after second shot of BNT162b2 mRNA COVID-19 vaccine. Antibody immunoglobulin G against the spike protein subunit of SARS-CoV-2 was semi-quantitatively measured using 4 commercial enzyme-linked immunosorbent assay kits. Factors affecting anti-SARS-CoV-2 antibodies levels were investigated.</p><p><strong>Results: </strong>Fifty-one persons (22 - 54 years, male sex; 19.6%) were enrolled and all participants acquired anti-SARS-CoV-2 antibodies in four diagnostic kits. Anti-SARS-CoV-2 antibodies were strongly correlated between diagnostic kits; SG Medical and Genscript (r = 0.942), SG Medical and HB Healthcare (r = 0.903), and HB Healthcare and Genscript (r = 0.868). We investigated factors affecting antibody level using SG medical kit. The median inhibition was 93.1%, and 84.0% of participants showed >90.0% inhibition. Systemic adverse event severity had no association with the anti-SARS-CoV-2 antibodies level. Antibody level was inversely correlated with weight (-0.312, <i>P</i> = 0.027), body mass index (BMI) (r = -0.303, <i>P</i> = 0.032), and body surface area (r = -0.285, <i>P</i> = 0.044). In multivariate analysis, the upper 50% of anti-SARS-CoV-2 antibodies (≥93.1%) was inversely associated with weight (odds ratio [OR]: 0.19; 95% confidence interval [CI]: 0.04 - 0.83 in weight ≥55kg) and BMI (OR: 0.12; 95% CI: 0.03 - 0.61 in BMI ≥22 kg/m²).</p><p><strong>Conclusion: </strong>Anti-SARS-CoV-2 antibody was inversely correlated with weight and BMI, which may be used as a marker to predict immune response of BNT162b2 mRNA vaccination in young and middle aged adults.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT05083026.</p>","PeriodicalId":520645,"journal":{"name":"Infection & chemotherapy","volume":" ","pages":"504-516"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7f/97/ic-54-504.PMC9533164.pdf","citationCount":"1","resultStr":"{\"title\":\"Body Weight is Inversely Associated with Anti-SARS-CoV-2 Antibody Levels after BNT162b2 mRNA Vaccination in Young and Middle Aged Adults.\",\"authors\":\"Su Youn Nam, Seong Woo Jeon, Deuk Kju Jung, Sung-Jae Heo\",\"doi\":\"10.3947/ic.2022.0089\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>This study aimed to determine factors affecting serum levels of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies 2 months after coronavirus disease 2019 (COVID-19) vaccination in young and middle aged healthy adults.</p><p><strong>Materials and methods: </strong>Healthcare workers who have no history of SARS-CoV-2 infection, were enrolled at 2 months after second shot of BNT162b2 mRNA COVID-19 vaccine. Antibody immunoglobulin G against the spike protein subunit of SARS-CoV-2 was semi-quantitatively measured using 4 commercial enzyme-linked immunosorbent assay kits. Factors affecting anti-SARS-CoV-2 antibodies levels were investigated.</p><p><strong>Results: </strong>Fifty-one persons (22 - 54 years, male sex; 19.6%) were enrolled and all participants acquired anti-SARS-CoV-2 antibodies in four diagnostic kits. Anti-SARS-CoV-2 antibodies were strongly correlated between diagnostic kits; SG Medical and Genscript (r = 0.942), SG Medical and HB Healthcare (r = 0.903), and HB Healthcare and Genscript (r = 0.868). We investigated factors affecting antibody level using SG medical kit. The median inhibition was 93.1%, and 84.0% of participants showed >90.0% inhibition. Systemic adverse event severity had no association with the anti-SARS-CoV-2 antibodies level. Antibody level was inversely correlated with weight (-0.312, <i>P</i> = 0.027), body mass index (BMI) (r = -0.303, <i>P</i> = 0.032), and body surface area (r = -0.285, <i>P</i> = 0.044). In multivariate analysis, the upper 50% of anti-SARS-CoV-2 antibodies (≥93.1%) was inversely associated with weight (odds ratio [OR]: 0.19; 95% confidence interval [CI]: 0.04 - 0.83 in weight ≥55kg) and BMI (OR: 0.12; 95% CI: 0.03 - 0.61 in BMI ≥22 kg/m²).</p><p><strong>Conclusion: </strong>Anti-SARS-CoV-2 antibody was inversely correlated with weight and BMI, which may be used as a marker to predict immune response of BNT162b2 mRNA vaccination in young and middle aged adults.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT05083026.</p>\",\"PeriodicalId\":520645,\"journal\":{\"name\":\"Infection & chemotherapy\",\"volume\":\" \",\"pages\":\"504-516\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7f/97/ic-54-504.PMC9533164.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infection & chemotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3947/ic.2022.0089\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection & chemotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3947/ic.2022.0089","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
摘要
背景:本研究旨在确定中青年健康成人在接种2019冠状病毒病(COVID-19)疫苗2个月后血清抗严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)抗体水平的影响因素。材料与方法:在第二次接种BNT162b2 mRNA COVID-19疫苗后2个月，招募无SARS-CoV-2感染史的医护人员。采用4种市售酶联免疫吸附测定试剂盒半定量测定抗SARS-CoV-2刺突蛋白亚基的抗体免疫球蛋白G。探讨影响sars - cov -2抗体水平的因素。结果:51人(22 ~ 54岁)，男性;19.6%)，所有参与者在四种诊断试剂盒中获得抗sars - cov -2抗体。不同诊断试剂盒间抗sars - cov -2抗体相关性强;SG Medical and Genscript (r = 0.942)、SG Medical and HB Healthcare (r = 0.903)和HB Healthcare and Genscript (r = 0.868)。采用SG医用试剂盒检测影响抗体水平的因素。中位抑制率为93.1%，84.0%的受试者抑制率>90.0%。全身不良事件严重程度与抗sars - cov -2抗体水平无相关性。抗体水平与体重(-0.312,P = 0.027)、体重指数(BMI) (r = -0.303, P = 0.032)、体表面积(r = -0.285, P = 0.044)呈负相关。在多变量分析中，50%以上的抗sars - cov -2抗体(≥93.1%)与体重呈负相关(优势比[OR]: 0.19;95%可信区间[CI]: 0.04 - 0.83(体重≥55kg)和BMI (OR: 0.12;95% CI: 0.03 - 0.61 (BMI≥22 kg/m²)。结论:抗sars - cov -2抗体与体重、BMI呈负相关，可作为预测中青年接种BNT162b2 mRNA免疫应答的指标。试验注册:ClinicalTrials.gov标识符:NCT05083026。
Body Weight is Inversely Associated with Anti-SARS-CoV-2 Antibody Levels after BNT162b2 mRNA Vaccination in Young and Middle Aged Adults.
Background: This study aimed to determine factors affecting serum levels of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies 2 months after coronavirus disease 2019 (COVID-19) vaccination in young and middle aged healthy adults.
Materials and methods: Healthcare workers who have no history of SARS-CoV-2 infection, were enrolled at 2 months after second shot of BNT162b2 mRNA COVID-19 vaccine. Antibody immunoglobulin G against the spike protein subunit of SARS-CoV-2 was semi-quantitatively measured using 4 commercial enzyme-linked immunosorbent assay kits. Factors affecting anti-SARS-CoV-2 antibodies levels were investigated.
Results: Fifty-one persons (22 - 54 years, male sex; 19.6%) were enrolled and all participants acquired anti-SARS-CoV-2 antibodies in four diagnostic kits. Anti-SARS-CoV-2 antibodies were strongly correlated between diagnostic kits; SG Medical and Genscript (r = 0.942), SG Medical and HB Healthcare (r = 0.903), and HB Healthcare and Genscript (r = 0.868). We investigated factors affecting antibody level using SG medical kit. The median inhibition was 93.1%, and 84.0% of participants showed >90.0% inhibition. Systemic adverse event severity had no association with the anti-SARS-CoV-2 antibodies level. Antibody level was inversely correlated with weight (-0.312, P = 0.027), body mass index (BMI) (r = -0.303, P = 0.032), and body surface area (r = -0.285, P = 0.044). In multivariate analysis, the upper 50% of anti-SARS-CoV-2 antibodies (≥93.1%) was inversely associated with weight (odds ratio [OR]: 0.19; 95% confidence interval [CI]: 0.04 - 0.83 in weight ≥55kg) and BMI (OR: 0.12; 95% CI: 0.03 - 0.61 in BMI ≥22 kg/m²).
Conclusion: Anti-SARS-CoV-2 antibody was inversely correlated with weight and BMI, which may be used as a marker to predict immune response of BNT162b2 mRNA vaccination in young and middle aged adults.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
